Company intelligence / Profile preview

Innexus Nutraceuticals

Amsterdam, North Holland, Netherlands

Ownership: Private
Development stage: Other

Overview

Innexus is a biotechnology company focused on developing a new generation of antibody-based therapeutics using its proprietary DX-technology. The company's platform is designed to enhance the efficacy and safety of monoclonal antibodies by improving their pharmacokinetics and biodistribution. Innexus aims to address unmet medical needs in oncology and autoimmune diseases by optimizing existing antibody treatments and developing novel candidates. By leveraging its DX-platform, the company seeks to create therapies with superior therapeutic windows and improved patient outcomes.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyAntibodyDX-platform
Industry: Biotech

Beyond the preview

Go deeper on Innexus Nutraceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innexus Nutraceuticals.

Explore the full profile